Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Carl Gordon acquired 1,000,000 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $15,000,000.00. Following the completion of the purchase, the director owned 1,348,825 shares of the company’s stock, valued at $20,232,375. This trade represents a 286.68% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Scribe Therapeutics Trading Up 11.1%
Shares of SCTX stock opened at $20.40 on Friday. Scribe Therapeutics Inc. has a one year low of $17.31 and a one year high of $25.49.
Recommended Stories
- Five stocks we like better than Scribe Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
